We have tested various HLA class I monoclonal antibodies with single recombinant HLA class I antigens immobilised on nitrocellulose membranes and analysed the results using a novel computer algorithm (XR1) that correlates antibody reactivity to both linear, and conformational epitopes. One of the aims of this investigation was to elucidate the rules for theoretical and experimentally deduced complex paratope epitope interactions; the data will be applied to construct a modified program for HLA antibody specificity analysis. XR1 analyses potential antibody epitopes by using both continuous and discontinuous sets of amino acids contained within the size of an antibody footprint. This philosophy allows for the detection of epitopes that rely on 3-D conformation such as those that combine residues on both -hel ices or combinations of side loops and helices. To refine the algorithm it was tested using well-defined MoAbs such as the HLA-B7/22/27/67/73+ve ME1 MoAb that crossreacts with HLA-B46. One solution (there are others) that XR1 suggested for this complex specificity is for a discontinuous primary epitope of R62-Q65-A71 that is influenced by P43-E45. Presence of R62-Q65-A71 with P43-M45, such as in B46, results in weaker reactivity, possibly due to restricted access to the primary epitope by the altered adjacent side loop. This type of 'fuzzy' epitope is also found in other MoAbs: screening of the HDG8D9 MoAb by immobilized recombinant HLA reveals a B35/51/18 specificity crossreacting with B52, B53 and B37: that can also be explained by an epitope that it is a combination of discontinuous residues at 43-45 and 62-71. These and other findings will be discussed. HLA class I molecules present peptides which are usually 8-10 amino acids in length, and which essentially contribute to the antigenicity of the molecule. For a variety of alleles, peptide motifs have been described, but few studies have addressed the question to which extent variants of the same allelic group differ in their peptide motifs. To answer this question for the HLA-A*66 group, we have sequenced the eluate of a recombinant A*6602 molecule, and compared it with peptide sequence data reported for A*6601. The truncated recombinant product of A*6602 was expressed in the HLA class I-deficient cell line LCL 721.221. Cell culture supernatant was purified by W6/32 affinity chromatography, peptides were isolated by acid elution, and the predominant peptide was isolated by RP-HPLC. By MALDI-TOF mass spectrometry its sequence was determined as KTKGSGFFV, representing a fragment of the human Ig chain C region. For A*6601, at position 2 of the bound peptide, T and V; and at position 9, R have been previously described as anchor residues, bound by pockets B and F, respectively. While deviations at position 9 also in A*6601 peptides have been described, position 2 corresponds to the anchor residue reported for A*6601. Both A*66 variants differ by position 163 (R E), shaping pockets A and B. Although this position has been described as critical regarding HLA class I allorecognition, the results suggest that in A*66 the R E exchange leaves the P2 anchor of the peptide unaffected. Thus, this variation appears not to alter significantly the binding characteristics of the A*66 pockets, which allows to expect a low allogenicity between A*6601 and A*6602. Although the causative role of the human histocompatibility antigen HLA-B27 in spondyloarthropathies is not understood, the molecule itself appears as the strongest predisposing factor for pathogenesis. The B*2709 subtype exhibits limited disease association and differs only at position 116 (His) of the heavy chain from the common, disease-associated subtype B*2705 (Asp116). Residue 116 occupies a crucial position within the F-pocket which accomodates the peptide C-terminus, suggesting that differential peptide binding by the subtypes could be related to F-pocket architecture and hence to disease development. To uncover the molecular basis for the differental disease association, we determined the crystal structures of both subtypes in complex with a model peptide (Hülsmeyer et al., J. Biol. Chem. 277, 2002, 47844-47853) and two naturally occurring peptides. In case of the model peptide, both subtypes exhibited very similar structures, but revealed subtle differences at the protein surface which could result in differential T-cell recognition. However, these findings still do not provide a clear explanation for the differential disease association at the atomic level, and might be related to the model character of the peptide. Therefore, we additionally crystallized B*2705 and B*2709 with two self-peptides. Although these are presented in the context of both subtypes, the presence of T-cells with activity against such peptides may be mainly observed in individuals typing as B*2705, suggesting that these individuals, but not those with B*2709, can possess T-cells which have not been appropriately deleted during thymic selection. The refinement of the crystal structures is still in progress, but it is already clear that one of the self-peptides adopts the canonical conformation when bound to B*2709, but shows two drastically The main weakness of the MHC peptide binding predictive models available is their inability to give an account of the interdepen-dence of the sequences properties within the peptide. Which amino acids are present at a particular position in the peptide must, to a certain degree, be determined by which amino acids are present at other positions in the peptide itself. Reducing the data to bipolar variables and using and propositional logic algorithm, the peptide subsets that bind to A*0201 and to B*27052 were analysed. In regard to A*0201 the following intrapeptide sequence dependecies were identified: 2T = f(4Q, 5V, 6P, 7F, 8S, 9V) , 1Y = f(4P, 5G, 6P, 7V, 8T, 9V), 1L = f(2L), 1I = f(4Q, 5V, 6P, 7F, 8S, 9V), 9L = f(1L, 3L, 4V, 6V, 7V), 1F = f(3Y, 4G), 2M = f(8G, 1Y), 2L = f(5G), 1S = f(4D, 7I), 1V = f(4G, 6L), 2I = f(4S), 2V = f(3M, 3I, 4P, 4Q), 6P = f(4P, 4Q, 4G, 1L, 3L, 4L, 5L, 6L, 7L, 8L, 9L), 3Y = f(2M, 1L, 1F, 4G, 2L), 3D = f(4Q, 4P, 4G, 4L, 6P), 3M = f(2M, 9V, 9L), 4P = f(5G, 6P, 7V, 6T), 4Q = f(5V, 6P, 7F, 8S, 9V). The A*0201 model showed a sensitivity of 90% and a specificity of 98% with new data. In regard to B*27052-bound peptides, a model was created with a sensitivity of 100% and a specificity of 99%. This model does not distinguish between the binding to HLA-B*2705 and to HLA-B*2709. It does distinguish, however, between binding peptides, on one hand, and peptides meeting the known binding characteristics for HLA-B*2705, but actually failing to bind experimentally, on the other hand. Usual methods assuming the independence of peptide amino acids in determining binding could not distinguish between the two groups. It was found that the interrelation of the amino acid at position 9 with the other amino acids played a more significant role.
We have tested various HLA class I monoclonal antibodies with single recombinant HLA class I antigens immobilised on nitrocellulose membranes and analysed the results using a novel computer algorithm (XR1) that correlates antibody reactivity to both linear, and conformational epitopes. One of the aims of this investigation was to elucidate the rules for theoretical and experimentally deduced complex paratope epitope interactions; the data will be applied to construct a modified program for HLA antibody specificity analysis. XR1 analyses potential antibody epitopes by using both continuous and discontinuous sets of amino acids contained within the size of an antibody footprint. This philosophy allows for the detection of epitopes that rely on 3-D conformation such as those that combine residues on both -hel ices or combinations of side loops and helices. To refine the algorithm it was tested using well-defined MoAbs such as the HLA-B7/22/27/67/73+ve ME1 MoAb that crossreacts with HLA-B46. One solution (there are others) that XR1 suggested for this complex specificity is for a discontinuous primary epitope of R62-Q65-A71 that is influenced by P43-E45. Presence of R62-Q65-A71 with P43-M45, such as in B46, results in weaker reactivity, possibly due to restricted access to the primary epitope by the altered adjacent side loop. This type of 'fuzzy' epitope is also found in other MoAbs: screening of the HDG8D9 MoAb by immobilized recombinant HLA reveals a B35/51/18 specificity crossreacting with B52, B53 and B37: that can also be explained by an epitope that it is a combination of discontinuous residues at 43-45 and 62-71. These and other findings will be discussed.
COMPARATIVE PEPTIDE BINDING CHARACTERISTICS OF HLA-A*66 ALLELIC VARIANTS
Christina Bade-Doeding, Britta Eiz-Vesper, Kathrin Hallensleben, Holger-A. Elsner, Joachim Kuhn, Rainer Blasczyk. Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany.
HLA class I molecules present peptides which are usually 8-10 amino acids in length, and which essentially contribute to the antigenicity of the molecule. For a variety of alleles, peptide motifs have been described, but few studies have addressed the question to which extent variants of the same allelic group differ in their peptide motifs. To answer this question for the HLA-A*66 group, we have sequenced the eluate of a recombinant A*6602 molecule, and compared it with peptide sequence data reported for A*6601. The truncated recombinant product of A*6602 was expressed in the HLA class I-deficient cell line LCL 721.221. Cell culture supernatant was purified by W6/32 affinity chromatography, peptides were isolated by acid elution, and the predominant peptide was isolated by RP-HPLC. By MALDI-TOF mass spectrometry its sequence was determined as KTKGSGFFV, representing a fragment of the human Ig chain C region. For A*6601, at position 2 of the bound peptide, T and V; and at position 9, R have been previously described as anchor residues, bound by pockets B and F, respectively. While deviations at position 9 also in A*6601 peptides have been described, position 2 corresponds to the anchor residue reported for A*6601. Both A*66 variants differ by position 163 (R E), shaping pockets A and B. Although this position has been described as critical regarding HLA class I allorecognition, the results suggest that in A*66 the R E exchange leaves the P2 anchor of the peptide unaffected. Thus, this variation appears not to alter significantly the binding characteristics of the A*66 pockets, which allows to expect a low allogenicity between A*6601 and A*6602. Although the causative role of the human histocompatibility antigen HLA-B27 in spondyloarthropathies is not understood, the molecule itself appears as the strongest predisposing factor for pathogenesis. The B*2709 subtype exhibits limited disease association and differs only at position 116 (His) of the heavy chain from the common, disease-associated subtype B*2705 (Asp116). Residue 116 occupies a crucial position within the F-pocket which accomodates the peptide C-terminus, suggesting that differential peptide binding by the subtypes could be related to F-pocket architecture and hence to disease development. To uncover the molecular basis for the differental disease association, we determined the crystal structures of both subtypes in complex with a model peptide (Hülsmeyer et al., J. Biol. Chem. 277, 2002, 47844-47853) and two naturally occurring peptides. In case of the model peptide, both subtypes exhibited very similar structures, but revealed subtle differences at the protein surface which could result in differential T-cell recognition. However, these findings still do not provide a clear explanation for the differential disease association at the atomic level, and might be related to the model character of the peptide. Therefore, we additionally crystallized B*2705 and B*2709 with two self-peptides. Although these are presented in the context of both subtypes, the presence of T-cells with activity against such peptides may be mainly observed in individuals typing as B*2705, suggesting that these individuals, but not those with B*2709, can possess T-cells which have not been appropriately deleted during thymic selection. The refinement of the crystal structures is still in progress, but it is already clear that one of the self-peptides adopts the canonical conformation when bound to B*2709, but shows two drastically different conformations when presented by B*2705. The results indicate why thymic selection against this peptide in the frameworks of B*2705 and B*2709 may yield different T-cell repertoires, and have general implications for the development of autoimmunity. The main weakness of the MHC peptide binding predictive models available is their inability to give an account of the interdepen-dence of the sequences properties within the peptide. Which amino acids are present at a particular position in the peptide must, to a certain degree, be determined by which amino acids are present at other positions in the peptide itself. Reducing the data to bipolar variables and using and propositional logic algorithm, the peptide subsets that bind to A*0201 and to B*27052 were analysed. In regard to A*0201 the following intrapeptide sequence dependecies were identified:
INTERNAL RELATIONS BETWEEN PEPTIDE AMINO ACIDS AT DIFFERENT POSITIONS
The A*0201 model showed a sensitivity of 90% and a specificity of 98% with new data. In regard to B*27052-bound peptides, a model was created with a sensitivity of 100% and a specificity of 99%. This model does not distinguish between the binding to HLA-B*2705 and to HLA-B*2709. It does distinguish, however, between binding peptides, on one hand, and peptides meeting the known binding characteristics for HLA-B*2705, but actually failing to bind experimentally, on the other hand. Usual methods assuming the independence of peptide amino acids in determining binding could not distinguish between the two groups. It was found that the interrelation of the amino acid at position 9 with the other amino acids played a more significant role. Understanding the interaction of peptides with MHC class I is important for tumor and viral vaccine development. Traditional studies utilize radio-labeled peptides and detergent solubilized class I MHC to detect MHC-peptide interactions on a solid phase. In this study, we utilize fluorescence polarization to investigate soluble class I MHC-peptide interactions in solution. We produce recombinant soluble HLA-A*0201 and B*0702 in a bioreactor system and determine MHC/peptide complex association constants as well as the equilibrium binding constants with several fluorescein isothiocyanate-labeled peptides. To complete the assay in solution, we utilized fluorescence polarization because it allows the direct measurement of the ratio between free and bound labeled ligand in solution without separation steps. To test the assay, we characterized more than 100 peptides of a putative cancer specific antigen for their ability to bind sHLA class I in this assay. The results demonstrate that the sHLA peptide binding assay is a versatile tool for characterizing the binding of single ligands as well as for rapid screening of large numbers of peptides. This assay represents an important tool for the identification of epitopes to be used in cancer and viral vaccines. MHC class I molecules present intracellularly derived peptides to immune effector cells; during intracellular viral infection, class I molecules bind and present fragments of virally derived proteins. Recognition of the antigenic peptide as foreign or virus derived ultimately leads to T-cell activation and destruction of the infected cells. Viruses, however, have derived multiple mechanisms for downregulation of class I molecules and hence the immune response against them. In fact, viruses alter multiple cellular pathways in order to both evade host immune responses and maximize viral production from the eukaryotic host. This changing protein complement inside the cell likely leads to changes in peptide presentation on the outside of the cell, however, this breadth and scope of these changes are currently unknown.
THE USE OF FLUORESCENCE POLARIZATION TO MONITOR CLASS I MHC-PEPTIDE INTERACTIONS IN SOLUTION

SELF-PROTEIN DERIVED PEPTIDES
In order to characterize the changes in epitope presentation that result from infection with HIV, we have developed an approach to identify class I presented peptides unique to infected cells. Class I presented peptides from HIV infected and uninfected cells are directly compared, and peptide epitopes unique to infected cells are sequenced. Briefly, we transfect CD4+ T cells to secrete a soluble class I molecule, in this study HLA-B*0702. Transfected cells are cultured in hollow-fiber bioreactors as either uninfected cells or after infection with HIV. Soluble HLA containing supernatant is collected as harvest, affinity purified, and the peptides released from the heavy chain using acid denaturation. Peptides are separated using reverse-phase HPLC to reduce complexity and then mapped using a Q-STAR Q-TOF mass spectrometer. Maps are then compared to identify peptides that are presented only or in higher proportion on infected cells. These peptides are then sequenced using tandem mass spectrometry.
Analysis of peptides upregulated or presented solely on HIV-infected cells using this system has yielded HIV derived epitopes and numerous peptides derived from selfproteins. For example, one such endogenous peptide, GPRTAALGLL, derives from the cellular protein reticulocalbin 2. Real-time PCR analysis was employed to show that reticulocalbin is not upregulated at the transcriptional level in T-cell transfectants infected with HIV. This suggests that reticulocalbin may be preferentially degraded or released from the endoplasmic reticulum during infection. Changes in self proteins presented as MHC bound peptides during infection therefore reflect the complex interaction between HIV and its host. Juvenile idiopathic arthritis (JIA) is an HLA-associated rheumatic disease with onset in childhood. We recently reported that allele 5 at microsatellite (MS) D6S265 (located near HLA-A) is associated with JIA, independent of linkage disequilibrium (LD) with the high risk DR8-DQ4 haplotype. In the present study we investigate if alleles at D6S265 or other markers in the implicated region are associated with JIA also on other HLA backgrounds. We investigated 94 patients with JIA and 246 healthy, unrelated controls from Norway. All patients and controls carried either DR5-DQ7 or DR6-DQ6 haplotypes. We genotyped 10 MS markers covering ~2 Mb of the HLA region around marker D6S265. Expectation-maximization algorithm was used to estimate haplotypes and the distribution of MS alleles on the DR5-DQ7 or DR6-DQ6 haplotypes were compared between patients and controls, in order to exclude association secondary to LD with these DR-DQ genes.
On the DR6-DQ6 haplotype the strongest association was observed for allele 6 at the D6S265 marker (OR = 5.9, Pc = 0.003). On the DR5-DQ7 haplotype a tendency for positive associations was observed for allele *172 at the D6S2704 marker (located ~230 kb centromeric to D6S265) (OR= 4.1, Pnc= 0.003, Pc = ns), and for allele *3 at D6S265 (OR=2.5, Pnc= 0.04, Pc= NS).
Our result further support the presence of a novel JIA susceptibility gene in the HLA class I, being in LD with the D6S265 marker, which is additional to the association provided by the DR-DQ genes.
CONSTRUCTION OF A HIGH-DENSITIY SINGLE NUCLEO-TIDE POLYMORHISM (SNP) MAP OF THE HLA-C REGION IN THE HUMAN MHC
Kerstin Bade, Martina Wedler, Michael Weichenthal, Rajan P. Nair, James T. Elder, Dieter Kabelitz, Stefan Jenisch Institute of Immunology, University of Kiel, Germany
The major susceptibility region for familial psoriasis, PSORS1, is supposed to be located close to HLA-C in the human MHC. In order to achieve fine mapping of PSORS1, we have constructed a high density SNP map of this area. TCF19, POU5F1, and HCGII-2 telomeric, and HCGIV-II centromeric of HLA-C were investigated. This region encompasses 113 kb. Possible coding sequences were identified by the programs FGENESH and GENESCAN and analysed by direct DNA-sequencing. 62 healthy individuals derived from 17 caucasian families were analysed. Each SNP identified was validated by segregation analysis and replicated sequencing. For final acceptance, SNPs had to be present on at least two independent haplotypes, all possible genotypes had to be detectable, and segregation analysis had to be consistent. According to these criteria, a total of 68 SNPs was identified. TCF19 (4701 bp analysed, 9 SNPs) and POU5F1 (4500 bp, 12 SNPS) yielded mean distances between SNPs of 358 and 333 bp respectively, with maximum distances between SNPs of 896 bp observed for POU5F1 and 1311 for TCF19. In contrast to these genes, the telomeric loci demonstrated a much higher SNP density (NOB4: 30 SNPs in 900 bp; HCGII-2: 13 SNPs in 3295 bp; HCGIV-2; 4 SNPs in 370 bp) with maxium distances of 683 bp (NOB4), 134 bp (HCGII-2), and 90 bp (HCGIV-2). A highly polymorphic area in the TCF19 region encompassing 35 bp and 25 SNPs, and a total of 9 insertions, 8 of them in the POU5F1 region, were identified. Taken together, the resulting SNP map supplies the information required for further finemapping of the psoriasis susceptibility locus PSORS1.
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ANALYSIS OF THE MIC-B POLYMORPHISM AND ITS ASSOCIATION WITH PSORIASIS
Andrea Eymess, Michael Weichenthal, Martina Wedler, Rajan P. Nair, James T. Elder, John J. Voorhees, Enno Christophers, Dieter Kabelitz, Stefan Jenisch Institute of Immunology, University of Kiel, Germany
Familial psoriasis is associated with several HLA class I antigens, the most prominent being HLA-Cw6. The major genetic risk region for psoriasis, PSORS1, is assumed to extend from CDSN telomeric of HLA-C to MIC-B centomeric of HLA-B. In the current study, the allelic organization of the MIC-B gene and its associaton with psoriasis was analysed. A total of 87 individuals (60 affected) derived from 14 families were analysed. From all individuals, the coding region of exons 2,3,4 and 5 were sequenced. Hereby identified single nucleotide polymorphisms (SNPs) were validated by segregation anlysis. A total of 10 SNPs could be identified which could be grouped into 13 alleles. Association of the MIC-B, HLA-B,and HLA-C alleles with psoriasis was analyzed by the transmission disequilibrium test (TDT). Due to the small sample size, no significant association was observed after correction for multiple testing. However, the highest transmission ratio (11/2, p=0.011) was observed for one allele of the MIB-B gene, whereas the strongly associated HLA-alleles Cw6 and HLA-B57 yielded lower risks (6/2 and 8/3; n.s.). In addition, one family was present in the study in which a recombination event occurred on a chromosome positive for both the HLA-Cw6-B57 haplotype and the MIC-B risk allele. The breakpoint on this chromome is located between HLA-B and MIC-B; and the centromeric part of the chromosome positive for the respective MIC-B allele was transmitted to an affected offspring, whereas Cw6-B57 was not passed to this patient. Genetic susceptibility to coeliac disease is strongly associated with HLA-DQA1*05-DQB1*02 (DQ2) and HLA-DQA1*03-DQB1*0302 (DQ8). Study of the HLA associations in patients not carrying these heterodimers has been limited by the rarity of such patients. This European collaboration has provided a unique opportunity to study a large series of such patients. From 1008 European coeliacs, 61 were identified who neither carry the DQ2 nor DQ8 heterodimers. Fifty seven of these encoded half of the DQ2 heterodimer. The remaining 4 patients had a variety of clinical presentations. Three of them carried the DQA1*01-DQB*05 haplotype as did 20/61 of those carrying neither DQ2 nor DQ8. This may implicate a role of the DQA1*01-DQB*05 haplotype. None of these four patients carried the DQB1*06 allele that has previously been reported in this sub-group of patients. Of the 16 DQ2 heterodimer negative patients without DRB1*04 or DRB1*07 haplotypes, it was inferred that none encoded the previously implicated DRB4 gene as none had a DRB1*09 haplotype. These results underline the primary importance of HLA-DQ alleles in susceptibility to coeliac disease, and the extreme rarity of coeliac patients carrying neither the DQ2 or DQ8 heterodimers nor one half of the DQ2 heterodimer alone.
HLA AND NK RECEPTOR GENES IN HIV PROGRESSION Frank T Christiansen, Corey B Moore, Dianne De Santis, Silvana Gaudieri, Campbell S Witt, Ian R James and Simon A Mallal DCIBG, Royal Perth Hospital, CCIBS, Murdoch University, University of Western Australia, Perth Western Australia NK cell receptors and HLA molecules are intimately involved in the immune response against viral infections. The killer immunoglobulin-like receptors (KIRs) on NK cells regulate responses via the recognition of particular HLA class I products on the surface of infected cells. At the genomic level, both genetic systems are highly polymorphic and have recognised haplotypes, which adds complexity to their interaction. Previously, we and others have shown the association of HLA class I with HIV progression. More recently, the Carrington group observed a synergistic effect involving the activating KIR3DS1 allele and HLA-B Bw4-80Ile on the progression to depletion of CD4+ T cells, suggestive of an interactive model in the immune response to HIV infection.
To further investigate the relationship between the two genetic systems, we examined changes in viral load in 249 pre-treatment patients from the Western Australia HIV cohort. Genetic variants known to affect HIV progression were associated with changes in HIV-1 viral load. However, we could not show a significant association with KIR3DS1 nor the epistatic effect with Bw4-80Ile. When we examined only those patients with known seroconversion dates, we found that the KIR3DS1 allele was associated with rapid progression to depletion of CD4+ T cells (p=0.01). We did not have sufficient statistical power to determine the KIR3DS1 and Bw4-80Ile relationship, but suggest that other KIR genes may be involved.
We suggest that further analyses of haplotypes in both genetic systems is needed to understand their complex interactions in driving NK cell responses to HIV and disease.
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